News & Events

Pipeline Therapeutics Changes Name to Contineum Therapeutics to Reflect Expanded Focus on NI&I Therapeutic Indications (Neuroscience, Inflammation and Immunology)

Pipeline Therapeutics to Participate in Upcoming Investor Conferences

Pipeline Therapeutics to Participate in Multiple Upcoming Investor Conferences

Pipeline Therapeutics Announces First Subject Dosed with PIPE-791 in Phase 1 Study

BOLD Innovation That Matters: Episode III Podcast Interview with Carmine Stengone

Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1 Study of PIPE-791

Pipeline Therapeutics to Present at the 2023 Jefferies Global Healthcare Conference

Pipeline Therapeutics to Present at the 2023 RBC Global Healthcare Conference

Pipeline Therapeutics Announces Global License and Development Agreement for Investigational Neuroscience Therapy, PIPE-307

Pipeline Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Pipeline Therapeutics Announces Participation at the 2023 Stifel CNS Days Conference

Pipeline Therapeutics to Present Preclinical Poster on PIPE-791 at the Glial Biology: Functional Interactions Among Glia Neurons, a Gordon Research Conference (GRC)

Pipeline Therapeutics to Present Multiple Posters at SFN 2022 Neuroscience Annual Meeting

Pipeline Therapeutics Announces Participation in Upcoming Investor Conferences in November

Pipeline Therapeutics Announces Participation in Upcoming Investor Conferences

Pipeline Therapeutics to Participate in the UBS Virtual Biotechnology Private Company Symposium

Pipeline Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

Pipeline Therapeutics to Present at Multiple Investor Conferences in May 2022

Pipeline Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference

Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b/2a Study of PIPE-307 in Patients with Relapsing-Remitting Multiple Sclerosis 

Pipeline Therapeutics to Present at Upcoming March Investor Conferences

Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple Sclerosis

Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors

Pipeline Therapeutics to Participate in the Stifel 2021 Virtual Healthcare and Jefferies London Healthcare Conferences

Pipeline Therapeutics Initiates Phase 1 Clinical Trial of PIPE-307

Pipeline Therapeutics Completes $80 Million Series C Financing

Pipeline Therapeutics to Participate in the 2020 RBC Capital Markets and SVB Leerink Private Company Conferences

Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

Pipeline Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Pipeline Therapeutics to Present at Stifel 2020 Virtual Healthcare Conference

Pipeline Therapeutics Appoints Peter Slover as Chief Financial Officer

Pipeline Therapeutics to Present at BMO’s Fall Private Company Showcase 2020

Pipeline Therapeutics Appoints Lori Lyons-Williams to its Board of Directors

Pipeline Therapeutics to Present at Two Upcoming Investor Conferences

Pipeline Therapeutics to Present at Three Upcoming Investor Conferences

Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss

Pipeline Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference

Pipeline Therapeutics to Participate in the 19th Annual Needham Virtual Healthcare Conference

Pipeline Therapeutics to Participate in the SVB Leerink 9th Annual Global Healthcare Conference

Pipeline Therapeutics Completes $30 Million Series B Financing

Pipeline Therapeutics to Participate in the Stifel 2019 Healthcare Conference

Pipeline Therapeutics to present at the Society for Neuroscience’s 49th Annual Meeting in Chicago

New MS Therapy Company, Pipeline, to Focus on Rejuvenating Coating That Protects Nerve Cells